Alpha Tau Medical (NASDAQ:DRTS) CFO Raphi Levy Sells 2,270 Shares of Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 2,270 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $14.00, for a total transaction of $31,780.00. Following the completion of the sale, the chief financial officer directly owned 90,180 shares of the company’s stock, valued at $1,262,520. The trade was a 2.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Thursday, July 2nd, Raphi Levy sold 17,873 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.00, for a total transaction of $232,349.00.
• On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The shares were sold at an average price of $13.02, for a total transaction of $27,693.54.
• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total transaction of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $11.00, for a total transaction of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Stock Down 6.0%

NASDAQ:DRTS opened at $12.76 on Wednesday. Alpha Tau Medical Ltd. has a 1 year low of $2.87 and a 1 year high of $14.11. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.09. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -19.04 and a beta of 1.17. The stock has a 50-day moving average price of $10.06 and a two-hundred day moving average price of $8.02.

Alpha Tau Medical (NASDAQ:DRTS) last released its quarterly earnings data on Monday, May 18th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.13). As a group, equities analysts expect that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Trifecta Capital Advisors LLC bought a new stake in Alpha Tau Medical during the 4th quarter worth about $48,000. Envestnet Asset Management Inc. bought a new position in shares of Alpha Tau Medical in the 3rd quarter valued at about $62,000. Principal Financial Group Inc. bought a new position in shares of Alpha Tau Medical in the 1st quarter valued at about $132,000. Bank of America Corp DE increased its position in shares of Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after acquiring an additional 21,677 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after acquiring an additional 17,500 shares during the last quarter. Institutional investors own 2.65% of the company’s stock.

Analyst Ratings Changes

DRTS has been the subject of several research reports. Piper Sandler increased their price objective on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 19th. Zacks Research cut shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 1st. Barclays upped their target price on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday, June 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Monday, April 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Alpha Tau Medical in a research note on Tuesday, June 2nd. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $12.60.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.